According to Innoviva's latest financial reports and stock price the company's current Operating Margin is 86.60%. At the end of 2021 the company had an Operating Margin of 113.63%.
Year | Operating Margin | Change |
---|---|---|
2021 | 113.63% | 8.03% |
2020 | 105.18% | 17.88% |
2019 | 89.23% | 10.76% |
2018 | 80.56% | 30.32% |
2017 | 61.81% | 38.68% |
2016 | 44.57% | -228.18% |
2015 | -34.77% | -96.01% |
2014 | -871.93% | -75.7% |
2013 | -3,587.66% | 26167.61% |
2012 | -13.66% | -97.1% |
2011 | -470.56% | 45.53% |
2010 | -323.34% | -1.75% |
2009 | -329.10% | -13.41% |
2008 | -380.09% | -50.39% |
2007 | -766.13% | -16.25% |
2006 | -914.74% | -26.27% |
2005 | -1,240.72% | 7.28% |
2004 | -1,156.54% | -42.46% |
2003 | -2,010.15% | -96.23% |
2002 | -53,258.33% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() OPKO Health
OPK | -36.36% | -141.99% | ๐บ๐ธ USA |
![]() Onconova Therapeutics ONTX | -8,391.15% | -9,789.55% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.